<DOC>
	<DOCNO>NCT02477202</DOCNO>
	<brief_summary>Combination-type oral contraceptive ( COCs ) show significantly reduce risk invasive epithelial ovarian cancer ( IEOC ) ; protective effect may achieve large extent COCs ability reduce cell proliferation fallopian tube fimbria ( FTF ) . The progestin-releasing Mirena® intra-uterine device ( IUD ) increasingly popular method contraception , know use reduce woman 's risk IEOC . Mirena® use block ovulation woman may release sufficient progestin also reduce cell proliferation FTF . This study aim evaluate effect Mirena® IUD cell proliferation FTF possible biomarker protection IEOC .</brief_summary>
	<brief_title>Mirena® IUD 's Effect Fallopian Tube Fimbriae Ovarian Cortical Inclusion Cyst Cell Proliferation</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Women 35 50 year age ( inclusive ) Women schedule undergo RRSO RRs Women least one fallopian tube remove riskreducing reason ( without removal ovar ( y ) ) Women willing Mirena® IUD insert least prior riskreducing surgery already Mirena® place Women use nonhormonal form contraception ( Note : If copper IUD use , IUD must remove prior time Mirena insertion . ) Any medical contraindication use Mirena® IUD , include : Pregnancy ( pregnancy test require prior study entry ) Known uterine anomaly distorts shape uterine cavity Acute pelvic inflammatory disease Postpartum endometritis endometrial infection Known suspect uterine cervical neoplasia Known history suspect breast cancer progestinsensitive cancer Uterine bleed unknown etiology . Untreated acute cervicitis , vaginitis , low genital tract infection Acute liver disease liver tumor ( benign malignant ) Use tamoxifen , raloxifene , chemotherapy within previous 6 month Positive pregnancy test Breastfeeding Use copper IUD patient willing remove prior surgery replace Mirena® IUD</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Mirena® IUD 's</keyword>
	<keyword>Women</keyword>
	<keyword>risk-reducing salpingo-oophorectomy</keyword>
	<keyword>risk-reducing salpingectomy</keyword>
</DOC>